HOME_PAGE_HEADER_CONTENT
Passion for Innovation.
Compassion for Patients.®
Creating New Standards of Care
Creating New Standards of Care
We create essential medicine for longer, better lives.
Learn More About Our PurposeRecentStoryCarousel
Our Stories
Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories
Each patient journey is unique for those faced with a breast cancer diagnosis. At Daiichi Sankyo, we strive to deepen our understanding beyond the scientific aspects, distinguishing between the personal needs of patients with early-stage versus metastatic breast cancer.
Learn more
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
Learn moreTransforming Science into Medicines
Transforming Science into Medicines
By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.
Learn More About Our Science
Dxd Section
Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology
DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.
Featured News
What's New
Read our press releases and learn more about our latest breakthroughs in medicine. View More News
Wed Jul 09 00:00:00 GMT-05:00 2025
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 TrialFinal long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial showed a sustained clinical benefit from long-term treatment with TURALIO® (pexidartinib) in patients with symptomatic tenosynovial giant cell tumor (TGCT) not amenable to improvement with surgery. These results, consistent with the primary analysis of the trial, were recently published in The Oncologist.
Learn moreMon Jun 23 00:00:00 GMT-05:00 2025
DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerBased on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial. Second U.S. approval for Daiichi Sankyo and AstraZeneca’s DATROWAY in less than six months.
Learn moreNew Home Pipeline
A Pipeline Pushing Us to Become a Global Leader in Oncology
Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.
Learn More About Our MedicinesNew Home With Purpose
Work with a Purpose
Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.
Join Our Team